# Antibody and Safety Study of 6 Doses of NicVAX in Smokers

> **NCT00598325** · PHASE1,PHASE2 · COMPLETED · sponsor: **Nabi Biopharmaceuticals** · enrollment: 74 (actual)

## Conditions studied

- Smoking

## Interventions

- **BIOLOGICAL:** 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)

## Key facts

- **NCT ID:** NCT00598325
- **Lead sponsor:** Nabi Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2012-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00598325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00598325, "Antibody and Safety Study of 6 Doses of NicVAX in Smokers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00598325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*